SY-1425 Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
Status:
Recruiting
Trial end date:
2029-02-08
Target enrollment:
Participant gender:
Summary
This study compares the efficacy of SY-1425 in combination with azacitidine to azacitidine in
combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA)
positive, and newly diagnosed with higher-risk myelodysplastic syndrome (MDS), and who have
not received treatment for this diagnosis. The primary goal of the study is to compare the
complete remission rate between the two treatment arms.